Quoin Pharmaceuticals Ltd. Amortization of Intangible Assets
Quoin Pharmaceuticals Ltd. (QNRX) reported Amortization of Intangible Assets of $25.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-14
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for the quarter ending 2026-06-30 was $25.00K, a 0.00% change year-over-year.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for the quarter ending 2026-03-31 was $25.00K, a 0.00% change year-over-year.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for the quarter ending 2025-12-31 was $25.00K, a 0.00% change year-over-year.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for the quarter ending 2025-09-30 was $25.00K, a 0.00% change year-over-year.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for fiscal 2024 was $100.00K, a 3.57% decline from fiscal 2023.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for fiscal 2023 was $103.71K, a 0.32% decline from fiscal 2022.
- Quoin Pharmaceuticals Ltd. amortization of intangible assets for fiscal 2022 was $104.04K, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.00K 10-Q · filed 2026-08-14 | $50.00K 10-Q · filed 2026-08-14 | $75.00K derived: sum of 3 quarters · filed 2026-08-14 | $100.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-07 | $50.00K derived: sum of 2 quarters · filed 2026-05-07 | $75.00K derived: sum of 3 quarters · filed 2026-05-07 | $100.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $50.00K derived: sum of 2 quarters · filed 2026-03-26 | $75.00K derived: sum of 3 quarters · filed 2026-08-14 | $100.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $25.00K 10-Q · filed 2025-11-06 | $50.00K derived: sum of 2 quarters · filed 2026-08-14 | $75.00K 10-Q · filed 2025-11-06 | $100.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $25.00K 10-Q · filed 2026-08-14 | $50.00K 10-Q · filed 2026-08-14 | $75.00K derived: sum of 3 quarters · filed 2026-08-14 | $100.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $25.00K 10-Q · filed 2026-05-07 | $50.00K derived: sum of 2 quarters · filed 2026-05-07 | $75.00K derived: sum of 3 quarters · filed 2026-05-07 | $100.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $50.00K derived: sum of 2 quarters · filed 2026-03-26 | $75.00K derived: sum of 3 quarters · filed 2026-03-26 | $100.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $25.00K 10-Q · filed 2025-11-06 | $50.00K derived: sum of 2 quarters · filed 2025-11-06 | $75.00K 10-Q · filed 2025-11-06 | $100.67K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $25.00K 10-Q · filed 2025-08-07 | $50.00K 10-Q · filed 2025-08-07 | $75.67K derived: sum of 3 quarters · filed 2025-08-07 | $101.67K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $25.00K 10-Q · filed 2025-05-13 | $50.67K derived: sum of 2 quarters · filed 2025-05-13 | $76.67K derived: sum of 3 quarters · filed 2025-05-13 | $102.67K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $25.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $51.67K derived: sum of 2 quarters · filed 2025-03-13 | $77.67K derived: sum of 3 quarters · filed 2025-03-13 | $103.71K 10-K · filed 2025-03-13 |
| 2023-09-30 | $26.00K 10-Q · filed 2024-11-08 | $52.00K derived: sum of 2 quarters · filed 2024-11-08 | $78.03K 10-Q · filed 2024-11-08 | $104.02K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $26.00K 10-Q · filed 2024-08-08 | $52.02K 10-Q · filed 2024-08-08 | $78.02K derived: sum of 3 quarters · filed 2024-08-08 | $104.02K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $26.01K 10-Q · filed 2024-05-09 | $52.02K derived: sum of 2 quarters · filed 2024-05-09 | $78.02K derived: sum of 3 quarters · filed 2024-05-09 | $104.02K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $26.01K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $52.01K derived: sum of 2 quarters · filed 2024-03-14 | $78.01K derived: sum of 3 quarters · filed 2024-03-14 | $104.04K 10-K · filed 2024-03-14 |
| 2022-09-30 | $26.00K 10-Q · filed 2023-11-09 | $52.00K derived: sum of 2 quarters · filed 2023-11-09 | $78.03K 10-Q · filed 2023-11-09 | $104.02K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $26.00K 10-Q · filed 2023-08-03 | $52.02K 10-Q · filed 2023-08-03 | $78.02K derived: sum of 3 quarters · filed 2023-08-03 | $104.02K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $26.01K 10-Q · filed 2023-05-09 | $52.02K derived: sum of 2 quarters · filed 2023-05-09 | $78.02K derived: sum of 3 quarters · filed 2023-05-09 | $104.02K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $26.01K derived: 10-K 12 month − 6-K 9 month · filed 2023-03-15 | $52.01K derived: sum of 2 quarters · filed 2023-03-15 | $78.01K derived: sum of 3 quarters · filed 2023-03-15 | $104.04K 10-K · filed 2023-03-15 |
| 2021-09-30 | $26.00K 6-K · filed 2022-11-10 | $52.00K derived: sum of 2 quarters · filed 2022-11-10 | $78.03K 6-K · filed 2022-11-10 | |
| 2021-06-30 | $26.00K 6-K · filed 2022-08-18 | $52.02K 6-K · filed 2022-08-18 | ||
| 2020-12-31 | $104.04K 20-F · filed 2022-04-14 | |||
| 2019-12-31 | $20.71K 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |